|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.12 USD | +2.49% |
|
+6.88% | -26.58% |
| 07-16 | RxSight Names Aziz Mottiwala as CEO | MT |
| 07-14 | Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026 | CI |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 2,587 | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | -25.58% | - |
| Enterprise Value (EV) | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 2,587 | 2,587 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | -25.58% | 0% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -28.8x | 36.2x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -0.9x | -0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 3.63x | 2.87x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.63x | 2.87x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -27.1x | 27.9x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -2.09 | 1.66 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 712.6 | 900.3 |
| EBITDA | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | - | - |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -95.28 | 92.63 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -92.71 | 82.72 |
| Net Debt | - | - | -198.3 | -222.5 | - | - | - |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 60.12 | 60.12 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,024 | - |
| Announcement Date | 14/03/22 | 13/03/23 | 27/02/24 | 25/02/25 | 23/02/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -28.77x | - | - | -.--% | 2.59B | |
| 17.64x | 3.78x | 9.76x | 0.58% | 67.88B | |
| 26.33x | 5.45x | 16.01x | 0.6% | 53.23B | |
| 37.7x | 12.83x | 24.43x | -.--% | 48.71B | |
| -43.2x | 3.1x | 9.18x | 3.5% | 38.98B | |
| 24.81x | 3.46x | 11.92x | -.--% | 29.55B | |
| 67.61x | 3.45x | 25.63x | -.--% | 23.75B | |
| -6.42x | 8.92x | -5.49x | -.--% | 22.07B | |
| -37.81x | 18.02x | -49.34x | -.--% | 16.49B | |
| 24.4x | 5.22x | 13.67x | -.--% | 16.57B | |
| Average | 8.23x | 7.14x | 6.20x | 0.47% | 31.98B | |
| Weighted average by Cap. | 14.55x | 6.49x | 10.45x | 0.65% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
